NEW YORK, NY / ACCESSWIRE / February 19, 2015 / “New To The Street” is pleased to announce its coverage of a six part series airing nationwide on two networks, featuring Accurexa, Inc. (OTCQB: ACXA) and its “BranchPoint Device”.
In this series, “New To The Street” will be doing high def interviews, covering all aspects of ACXAâ€™s “BranchPoint Device” including a discussion on their planned 2015 FDA 501K submission on the device and its feasibility of delivering dopaminergic neural stem cells, which has been demonstrated in animal studies, for the planned treatment of Parkinsonâ€™s Disease.
“New To The Street” will also go into ACXAâ€™s second product ACX-31 for the treatment of brain cancer.Â It is a chemotherapy product that delivers temozomide directly to the tumor site using the “BranchPoint Device” for the treatment of glioblastoma multi form, a malignant primary brain tumor. Noteworthy, the ACX -31 is contingent on the “BranchPoint Deviceâ€™s” FDA approval.
“Iâ€™m excited to be showcasing this product and the Accurexaâ€™s potential with the masses and believe the potential, when seen by the right sources, could be limitless,” says Vince Caruso, producer, “New To The Street”.
“We are thrilled to be featured in this series. We believe that our company is developing important novel therapies with our BranchPoint technology that address high unmet medical needs in the patient and physician community. We are glad that we have found enthusiastic supporters of our company in Vince and his team,” says Dr. George Yu, Accurexaâ€™s President & CEO.
About New to the Street
New to the Street paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis and public company profiles. New to the Street is produced by FMW Media Works Corp. a leading provider of business profiles and corporate special programming, and airs as paid-programming weekly in New York and monthly nationwide reaching more than 105 millionhomes, visit www.newtothestreet.com.
About Accurexa Inc.
The Company is focused on developing and commercializing novel neurological therapies based on its proprietary BranchPoint technology delivering therapeutics directly into specific regions of the brain. The BranchPoint device delivers therapeutics through the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Clinicians can “tailor” therapeutic delivery to individual patient anatomy and specific disease targets, which may enhance the efficacy of therapies. The BranchPoint device also gives physicians more precise control of the volume of therapeutics delivered and ensures that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. This modern and “easy to use” technology allows “real-time” monitoring of therapeutic delivery under interventional MRI guidance (iMRI), which can improve the accuracy of therapeutic delivery, reduce the risk of complications, and increase patient safety.
The BranchPoint device was developed at the University of California, San Francisco (UCSF) with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM). It is based on a neurosurgical delivery platform that the Company has exclusively licensed from UCSF. It can enable new approaches to neurological therapy and be modified for the delivery of a broad range of novel therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors. Additional information about the Company may be found on its website, www.accurexa.com.
Safe Harbor Statement
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the ability of the Company to successfully develop and commercialize novel neurological therapies based on its BranchPoint device and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes”, “expects”, or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Companyâ€™s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Companyâ€™s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.
New to the Street Contact
Email: [email protected]
SOURCE: Accurexa Inc.